ArticleScientific reports2025
The association of the systemic inflammation response index with the prognosis of primary retroperitoneal liposarcoma after surgical resection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Primary sclerosing epithelioid fibrosarcoma of the iliac fossa: a case report.Frontiers in oncology · 2026Article
- Nanohydrogels for Diabetic Wound Healing: Mechanisms, Applications, and Future Perspectives.International journal of nanomedicine · 2026Review
- Long-term survival with eribulin in an elderly patient with inoperable retroperitoneal well-differentiated liposarcoma: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Primary retroperitoneal liposarcoma (PRPLS) is a rare malignancy with a high risk of recurrence and poor prognosis. To evaluate the prognostic value of the systemic inflammation response index (SIRI) in patients with PRPLS undergoing curative-intent surgical resection and to compare its predictive performance with other inflammatory markers. This retrospective study included 122 patients with pathologically confirmed PRPLS who underwent surgical resection at Peking University International Hospital between January 2021 and January 2024. Patients were stratified into high-SIRI and low-SIRI groups based on an optimal cutoff value determined by receiver operating characteristic (ROC) curve analysis. Clinical characteristics, laboratory parameters, and surgical outcomes were compared between groups. Recurrence-free survival (RFS) and locoregional recurrence-free survival (LRFS) were assessed using Kaplan-Meier survival curves and log-rank tests. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify independent prognostic factors. Post-hoc power analysis was conducted to ensure sample adequacy. SIRI demonstrated the highest prognostic accuracy among evaluated inflammatory markers, with an AUC of 0.831 (P < 0.001), outperforming NLR (AUC = 0.724), PLR (AUC = 0.730), and MLR (AUC = 0.747). Patients with high SIRI (≥ 1.95) had significantly shorter RFS and LRFS compared to those with low SIRI (P < 0.001 and P = 0.008, respectively). High SIRI was associated with larger tumor size, higher Ki-67 index, abnormal liver function markers, elevated CRP, and lower albumin levels. In multivariate Cox regression analysis, SIRI remained the only independent predictor of RFS (HR = 5.19, 95% CI: 2.356, P < 0.001). Preoperative SIRI is an independent and superior prognostic biomarker for recurrence in patients with PRPLS following surgical resection. Compared to conventional inflammatory indices, SIRI shows stronger predictive value for both RFS and LRFS, offering a simple and effective tool for risk stratification in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.